Placebo News and Research

RSS

Pre-hospital treatment on the way to percutaneous coronary intervention

For patients with acute ST-segment-elevation AMI (STEMI) within 12 hours after symptom onset and with persistent ST-segment elevation, or new or presumednew left bundle-branch block with concomitant ST-segment elevation, restoring coronary blood flow as early as possible is the main goal of reperfusion strategies.

2 Sep 2008

The effects of A2 inhibitor Darapladib on human coronary athlerosclerotic plaque

A twelve month study of treatment with darapladib concluded that,Lp-PLA2 inhibition with darapladib prevented necrotic core expansion, a key determinant of plaque vulnerability.

2 Sep 2008

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Data from a phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy.

2 Sep 2008

Fibrin-derived peptide FX06 reduces cardiac reperfusion injury

Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.

2 Sep 2008

Overcoming poor response to standard oral antiplatelet agents

Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.

2 Sep 2008

Results from the Simvastatin and Ezetimibe in aortic stenosis study

The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and ezetimibe (10 mg daily) in patients with aortic stenosis.

2 Sep 2008

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Fluvastatin XL use is associated with improved cardiac outcome after major vascular surgery

The DECREASE III Study which took place in the Netherlands between June 2004 and April 2008, showed that patients treated with Fluvastatin showed an improved cardiac outcome after surgery.

1 Sep 2008

Faster heart rate linked to increased heart attack risk

A long-term study has revealed a link between a faster heart rate and the risk of a heart attack and the researchers say that heart disease patients with a pulse of more than 70 beats a minute are most at risk.

1 Sep 2008

The GISSI-HF trial: Effects of n-3 PUFA in 6,975 patients with symptomatic chronic heart failure

Researchers involved in the GISSI trial, concluded that simple, safe and cheap treatment with n-3 PUFA can provide a moderate beneficial advantage in terms of mortality and admission to hospital for cardiovascular reasons in patients with chronic heart failure, in a context of usual care.

31 Aug 2008

Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke

An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment.

31 Aug 2008

Magnesium sulfate decreases preterm infants' risk for cerebral palsy

Preterm infants born to mothers receiving intravenous magnesium sulfate - a common treatment to delay labor - are less likely to develop cerebral palsy than are preterm infants whose mothers do not receive it, report researchers in a large National Institutes of Health research network.

28 Aug 2008

Algeta reports positive phase II data on pain palliation with Alpharadin

Algeta ASA today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose.

28 Aug 2008

Epsom salt reduces risk of prem babies being born with cerebral palsy

A new study has found a simple way to reduce the risk of premature babies being born with cerebral palsy.

28 Aug 2008

Depression drug Cymbalta eases chronic back pain

A drug used to treat depression has been found to also be effective in reducing chronic low back pain.

28 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Olive leaf extract (EFLA943) helps tackle high blood pressure and cholesterol

Taking 1000mg of a specific olive leaf extract (EFLA943) can lower cholesterol and lower blood pressure in patients with mild hypertension (high blood pressure).

26 Aug 2008

Medication slows progression of myopia in children

Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).

26 Aug 2008

Good tidings for women on HRT

For many women struggling to deal with the symptoms of the menopause, the latest research on hormone replacement therapy (HRT) bears good tidings.

25 Aug 2008

Cymbalta approved in Europe for generalised anxiety disorder

Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD).

24 Aug 2008